atx inhibitor1

ATX inhibitor 1 is a potent ATX inhibitor with IC50 values of 1.23 nM (FS-3) and 2.18 nM (bis-pNPP).

ATX inhibitor 15 (compound 30) is an indole-based carbamate derivative with a strong inhibitory effect on autotaxin (ATX), demonstrated by an IC50 of 2.17 nM. It effectively inhibits ATX activity in vivo, suppresses the expression of pro-fibrotic genes, and exhibits protective effects in Bleomycin-induced lung fibrosis in mice [1].

ATX inhibitor 10 is a nitrogen-containing heterocyclic compound that is a potent inhibitor of ATX. Among other things, ATX plays a role in causing pathologies including fibrosis, neurodegeneration, arthritis, neuropathic pain, and cancer. ATX inhibitor 10 has shown research potential for ATX-related diseases.

ATX inhibitor 14, an indole-based carbamate derivative, is a potent inhibitor (IC50: 0.41 nM) of self-adhesive proteins (ATX) and has shown potential for research in fibrosis-related diseases.

ATX inhibitor 19 is a potent inhibitor of ATX (IC50: 156 nM).

ATX inhibitor 16 is a potent ATX inhibitor (IC50: 0.0021 μM) that exhibits a significant anti-proliferative effect on breast cancer cells.

ATX inhibitor 11 is a potent inhibitor of autotaxin (ATX) with an IC50 of 2.7 nM. ATX inhibitor 11 reduces fibrosis severity and decreases α-SMA deposition in mouse models of fibrosis. ATX inhibitor 11 is utilized in fibrosis-related research focused on lysophosphatidic acid signaling, extracellular matrix remodeling, and fibroblast activation mechanisms in pulmonary and tissue fibrosis models.

ATX inhibitor 13 (compound 10c) is an orally active ATX inhibitor (IC50: 3.4 nM) that arrests the cell cycle of RAW264.7 cells in the G2 phase, inhibits cell proliferation and migration, induces apoptosis, and exhibits an inhibitory effect on tumour colony formation.

ATX inhibitor 17, a powerful ATX inhibitor, exhibits an IC50 value of 0.019 µM, demonstrating significant anti-proliferative effects in breast cancer cells.